Related references
Note: Only part of the references are listed.Tumour necrosis factor α-308G→A polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis
Stephan Pavy et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
CD11c as a Transcriptional Biomarker to Predict Response to Anti-TNF Monotherapy With Adalimumab in Patients With Rheumatoid Arthritis
B. Stuhlmueller et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes
Vincent Goeb et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Gene expression profiling in rheumatoid arthritis: current concepts and future directions
E. J. M. Toonen et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Cytokines as therapeutic targets: Advances and limitations
Clemens Scheinecker et al.
IMMUNITY (2008)
Normalization strategies for mRNA expression data in cartilage research
K. Fundel et al.
OSTEOARTHRITIS AND CARTILAGE (2008)
The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab)
M. H. Buch et al.
RHEUMATOLOGY (2008)
Responsiveness to anti-tumour necrosis factor α therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients
T. C. van der Pouw Kraan et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
New therapies for treatment of rheumatoid arthritis
Josef S. Smolen et al.
LANCET (2007)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
D. E. Furst et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab
T. Lequerre et al.
RHEUMATOLOGY (2007)
Is IL-I a good therapeutic target in the treatment of arthritis?
Danielle Burger et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2006)
Development of a novel 2D proteomics approach for the identification of proteins secreted by primary chondrocytes after stimulation by IL-1 and oncostatin M
J. B. Catterall et al.
RHEUMATOLOGY (2006)
Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice
A. A. den Broeder et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk
Lawrence Goldkind et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
DE Furst et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates
P Wielinga et al.
CANCER RESEARCH (2005)
Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome
C Coulouarn et al.
HEPATOLOGY (2004)
Gene expression signatures for autoimmune disease in peripheral blood mononuclear cells
NJ Olsen et al.
ARTHRITIS RESEARCH & THERAPY (2004)
The safety of anakinra in high-risk patients with active rheumatoid arthritis - Six-month observations of patients with comorbid conditions
MH Schiff et al.
ARTHRITIS AND RHEUMATISM (2004)
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis - A large, international, multicenter, placebo-controlled trial
RM Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2003)
Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis
G Nuki et al.
ARTHRITIS AND RHEUMATISM (2002)
Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis
N Busso et al.
JOURNAL OF IMMUNOLOGY (2002)
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate - Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
S Cohen et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
